

Impact of Complete Revascularization for Multi-Vessel Disease

Seung-Jung Park, MD, PhD

Professor of Medicine, University of Ulsan College of Medicine
Asan Medical Center, Seoul, Korea

DES vs. CABG

for Multi-Vessel Disease


1. BARI 2D
2. FREEDOM
3. SYNTAX
4. BEST
5. Combined Patient Level Meta-Analysis

BARI 2D


Bypass Angioplasty Revascularization
Investigation 2 Diabetes ;
Focused on the Diabetes

BARI 2D: **PCI** vs. Medical Treatment (Lower Risk Diabetic Patients)

Survival




Freedom from MACE (death, MI, or stroke)




BARI 2D: CABG vs. Medical Treatment (Higher Risk Diabetic Patients)

Survival



Freedom from MACE (death, MI, or stroke)



FREEDOM


Future ***RE***vascularization ***E***valuation in
Patients with ***D***iabetes Mellitus: ***O***ptimal
Management of Multivessel Disease

BASELINE CHARACTERISTICS

	PCI	CABG	P value
No. of Patients	953	947	
Age, yrs	63.2 ± 8.9	63.1 ± 9.2	0.78
Male, %	73	70	0.08
Body Mass Index (Kg/m2)	29.7 ± 5.4	29.8 ± 5.3	0.08
Hypertension, %	85%	85%	0.75
Hyperlipidemia, %	84%	83%	0.66
Current smoker, %	15%	17%	0.31
Congestive heart failure, %	26%	28%	0.25
Prior Stroke	4%	3%	0.31
LV EF <40%	3%	2%	0.07
EuroScore	2.7 ± 2.4	2.8 ± 2.5	0.52
Syntax Score	26.2 ± 8.4	26.1 ± 8.8	0.77
Three vessel disease	82.3	84.5	0.22
No.of lesion	5.7 ± 2.2	5.7 ± 2.2	0.33
No.of stented lesion or graft vessel	3.5 ± 1.4	2.9 ± 0.8	NA
CTO lesion	6%	6%	0.99
Bifurcation lesion	22%	21%	0.06

FREEDOM (*Diabetics and MVD*)

Death / MI / Stroke at 5 Year




PCI/DES N	953	848	788	625	416	219	40
CABG N	943	814	758	613	422	221	44

SYNTAX (3VD Subset) MACCE to 5 Year

CABG (N=549)

TAXUS (N=546)



Cumulative KM Event Rate \pm 1.5 SE; log-rank *P* value; *Binary rates

DES vs. CABG *for Multi-Vessel Disease 2017*

CABG was superior to PCI with DESs in patients with diabetes and advanced CAD (predominantly, 3 VD).

However,
All Studies Used 1st Generation DES

BARI 2D	DES 35%, BMS 56%, Others
FREEDOM	SES 49%, PES 41%, Others
SYNTAX	PES 100%,

***Can We Make A
Better Clinical Outcomes
Using **New DES** ?***

BEST Study

Patients with
Multi-vessel Disease (Mainly 3VD)

R

```
graph TD; R((R)) --> PCI[PCI with Xience-V]; R --> CABG[CABG];
```

PCI with Xience-V

CABG

Primary Endpoint at 2 years:
Death + MI + Repeat R

PI : Park Seung-Jung

Baseline Clinical Characteristics

	PCI (N=438)	CABG (N=442)	P value
Age, years	64.0 ± 9.3	64.9 ± 9.4	0.13
Male sex	304 (69.4)	325 (73.5)	0.18
Body mass index	24.7 ± 2.9	25.0 ± 2.9	0.16
Diabetes	177 (40.4)	186 (42.1)	0.62
Hypertension	296 (67.6)	295 (66.7)	0.79
Hyperlipidemia	239 (54.6)	222 (50.2)	0.20
Current smoker	88 (20.1)	89 (20.1)	0.99
Previous PCI	30 (6.8)	38 (8.6)	0.33
Previous myocardial infarction	25 (5.7)	29 (6.6)	0.60
Previous congestive heart failure	16 (3.7)	12 (2.7)	0.43

Procedural Characteristics*


PCI	464
Total stents number	3.4 ± 1.4
Total stent length, mm	85.3 ± 38.2
Mean stent diameter, mm	3.1 ± 0.3
IVUS guidance	333 (71.8)
Complete revascularization	236 (50.9)†
CABG	401
Total no. of grafted vessels	3.1 ± 0.9
Total no. of arterial grafts	2.1 ± 1.1
Total no. of vein grafts	1.0 ± 0.8
Left internal mammary artery graft	398 (99.3)
Off-pump surgery	258 (64.3)
Complete revascularization	274/383 (71.5)†

* Data were summarized according to the as-treated analysis

† P<0.05 between PCI and CABG group

BEST ; 5 Years Outcomes

Primary End Point *Death, MI or TVR*




No. at Risk

PCI	438	402	362	305	242	126
CABG	442	415	377	326	262	145


***Primary End Point of SYNTAX,
(Death, MI, Stroke or Any
Repeat Revascularization)***

Death, MI, Stroke or Any RR *SYNTAX (3VD Subset)*



Death, MI, Stroke or Any RR

BEST




No. at Risk

PCI	438	389	341	288	229	117
CABG	442	409	368	317	250	137

Patient-Level Meta-Analysis (n=3,280)


Database Pooling of
SYNTAX (n=1800, PES),
BEST (n=880, EES), and
PRECOMBAT (n=600, SES) trials.

Patient-Level Meta-Analysis (n=3,280) MVD Subset / Death, MI or Stroke



BEST; Secondary Clinical Outcomes

Death, MI or Stroke




No. at Risk

	0	1	2	3	4	5
PCI	438	413	373	318	255	133
CABG	442	419	381	329	263	144

Event rates were derived from Kaplan-Meier estimates

Death




No. at Risk

Years Since Randomization

PCI	438	426	387	333	268	146
CABG	442	433	397	346	278	154

Event rates were derived from Kaplan-Meier estimates

Myocardial Infarction




No. at Risk

Years Since Randomization

PCI	438	419	382	325	261	140
CABG	442	422	386	335	271	151


Event rates were derived from Kaplan-Meier estimates

Land Mark Analysis of MI




Event rates were derived from Kaplan-Meier estimates

Land Mark Analysis of Death




Event rates were derived from Kaplan-Meier estimates

Land Mark Analysis of Death and MI



Event rates were derived from Kaplan-Meier estimates

Stroke




No. at Risk

	0	1	2	3	4	5
PCI	438	421	383	326	262	140
CABG	442	427	389	338	271	152


Event rates were derived from Kaplan-Meier estimates

Any Repeat Revascularization



Event rates were derived from Kaplan-Meier estimates

Target Lesion Revascularization




No. at Risk

Years Since Randomization

PCI	438	408	365	310	247	130
CABG	442	424	386	334	267	147

Event rates were derived from Kaplan-Meier estimates

New Lesion Revascularization



No. at Risk

	0	1	2	3	4	5
PCI	438	416	370	317	254	138
CABG	442	427	389	337	270	149

Event rates were derived from Kaplan-Meier estimates

Same Messages from **New York State Registry**

	PCI	CABG	HR (95% CI)	P value
	N=9223	N=9223		
Death at 3 year	3.1 %	2.86%	1.04 (0.93-1.17)	0.50
Myocardial infarction	1.87%	1.13%	1.51 (1.29-1.77)	<0.001
Stroke	0.72%	0.97%	0.62 (0.50-0.76)	<0.001
Revascularization	7.25%	3.10%	2.35 (2.14-2.58)	<0.001

Total 34,819 eligible patients, 9223 patients had similar propensity scores

What We've Learned *from Current Data*

Is the Game Over ?

Park SJ et al, NEJM. 2015; 372: 1204-1212

Bangalore S et al. N Engl J Med 2015; 372:1213-1222

Issue of Complete vs. Incomplete

Complete vs Incomplete *from New York Registry*

	PCI	CABG	HR (95% CI)	P value
Complete Revascularization	N=1911	N=1911		
Death at 3 year	2.54 %	2.50 %	1.08 (0.82-1.42)	0.58
Myocardial infarction	1.43%	1.37%	1.02 (0.71-1.47)	0.93
Stoke	0.42%	0.84%	0.43 (0.24-0.75)	0.003
Revascularization	5.46%	3.40%	1.55 (1.26-1.90)	<0.001
Incomplete Revascularization	N=7312	N=7312		
Death	3.25%	2.96%	1.03 (0.91-1.17)	0.63
Myocardial infarction	1.98%	1.07%	1.66 (1.39-1.98)	<0.001
Stoke	0.80%	1.01%	0.66 (0.52-0.83)	0.0004
Revascularization	7.70%	3.03%	2.59 (2.34-2.88)	<0.001

Complete vs Incomplete from *BEST Study*

	PCI	CABG	HR (95% CI)	P value
Complete Revascularization	N=215	N=295		
Death at 5 year	7.0%	4.4%	1.50 (0.71-3.15)	0.29
Myocardial infarction	2.3%	3.1%	0.75 (0.25-2.24)	0.60
Death, MI, or Stroke	11.6%	9.5%	1.18 (0.69-2.02)	0.55
Any repeat revascularization	6.5%	3.4%	1.89 (0.84-4.25)	0.13
MACCE	16.7%	12.2%	1.34 (0.84-2.13)	0.22
Incomplete Revascularization	N=215	N=122		
Death	6.5%	5.7%	1.22 (0.49-3.02)	0.68
Myocardial infarction	7.4%	1.6%	4.85 (1.11-21.1)	0.036
Death, MI, or Stroke	12.6%	9.0%	1.52 (0.75-3.07)	0.24
Any Repeat Revascularization	15.8%	10.7%	1.58 (0.83-3.00)	0.16
MACC	23.7%	16.4%	1.59 (0.94-2.66)	0.08



Complete vs Incomplete

from Meta-Analysis from SYNTAX, BEST and PRECOMBAT

PRECOMBAT

PCI

CABG




Patient at risk	0	1	2	3	4	5
CR	968	911	918	875	819	398
IR	724	689	651	602	545	291

Patient at risk	0	1	2	3	4	5
CR	1015	971	927	874	804	376
IR	505	474	461	437	411	221

Complete vs Incomplete


from Meta-Analysis from SYNTAX, BEST and PRECOMBAT

Death From Any Cause



Patient at risk	0	1	2	3	4	5
CABG	1538	1462	1403	1326	1224	549
PCI-IR	724	689	651	601	545	282
PCI-CR	968	941	918	875	819	389


Death, MI, or Stroke




Patient at risk	0	1	2	3	4	5
CABG	1538	1413	1349	1267	1160	565
PCI-IR	724	665	619	564	509	260
PCI-CR	968	916	886	839	776	373

Complete vs Incomplete from AMC MV Registry


Death




MI



Revascularization



Death, MI or Stroke



What We've Learned *from Current Data*

***Complete Revascularization Is
Important Practical Issue !***

Park SJ et al, NEJM. 2015; 372: 1204-1212

Bangalore S et al. N Engl J Med 2015; 372:1213-1222

Current Status of PCI

ESC Guidelines 2014

Elective PCI for 3 Vessel Disease

	CABG		PCI	
Recommendation according to extent of CAD	Class	Level	Class	Level
3 VD with a SYNTAX score ≤ 22	I	A	I	B
3 VD with a SYNTAX score 23 -32	I	A	III	B
3 VD with a SYNTAX score > 32	I	A	III	B

Reference; SYNTAX Study, .
Patrick, SW et al, NEJM. 2009 March 5;360(10)

**Does *SYNTAX* Score
(Angiographic Complexity) Really
Matter in Current PCI ?**

Impact of FFR for 3 Vessel Disease

*ationally,
nt*

*Totally Different World !
Different Concept !
We Need Different Data !*

Practical Guidelines, 2017

Elective PCI for 3 Vessel Disease

- 1. *If the Lesion is Favorable Anatomy for PCI, Complete Revascularization Should be Considered.***
- 2. *If the Lesion is Unfavorable Anatomy for PCI, Send the Patients to Surgery !***

PCI vs. CABG in Multi-Vessel Disease, **2017**

The Game Is Just Begun !